MedTrace Logo

Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

NCT00109798 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-09-19

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide and topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving temozolomide together with topotecan works in treating patients with primary CNS lymphoma.

Conditions

Interventions

DRUG

temozolomide

Patient will take drug on day 1-5 of 28 day schedule

DRUG

topotecan hydrochloride

Patient will have IV on days 2-6 on a 28-day schedule

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • The Methodist Hospital Research Institute

    lead OTHER

Principal Investigators

  • Pamela Z. New, MD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-07-31
Completion
2006-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109798 on ClinicalTrials.gov